Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Research analysts at Cantor Fitzgerald dropped their FY2020 EPS estimates for shares of Pfizer in a research report issued on Tuesday, July 30th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of $2.55 for the year, down from their prior forecast of $2.86.

Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm’s revenue was down 1.5% compared to the same quarter last year.

A number of other analysts have also commented on PFE. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Monday. Credit Suisse Group began coverage on Pfizer in a research report on Monday, July 15th. They issued a “hold” rating and a $47.00 target price for the company. Morgan Stanley lowered Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $48.00 to $40.00 in a research report on Tuesday. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. Fifteen analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $46.44.

Shares of Pfizer stock opened at $37.88 on Thursday. Pfizer has a one year low of $38.14 and a one year high of $46.47. The company has a market cap of $230.46 billion, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 2.42 and a beta of 0.64. The company has a 50-day moving average price of $43.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 3.80%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

In other Pfizer news, EVP Frank A. Damelio sold 153,184 shares of Pfizer stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the completion of the transaction, the executive vice president now owns 489,647 shares in the company, valued at approximately $21,588,536.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Weybosset Research & Management LLC raised its holdings in shares of Pfizer by 2.0% in the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 250 shares during the period. Congress Asset Management Co. MA raised its holdings in Pfizer by 2.0% during the 4th quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock valued at $578,000 after acquiring an additional 254 shares during the period. D.B. Root & Company LLC raised its holdings in Pfizer by 0.7% during the 4th quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock valued at $1,575,000 after acquiring an additional 255 shares during the period. Cottage Street Advisors LLC raised its holdings in Pfizer by 4.0% during the 4th quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 255 shares during the period. Finally, Financial Gravity Wealth Inc. raised its holdings in Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 257 shares during the period. Hedge funds and other institutional investors own 71.82% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What are no-load funds?

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.